(Q37031460)

17 August 2017

1 reference

title

Treatment of polymyalgia rheumatica/giant cell arteritis (English)

1 reference

17 August 2017

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80067-6

30 November 2022

author name string

V. Kyle

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1807823

30 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1807823

30 November 2022

publication date

1 December 1991

1 reference

full work available at URL

17 August 2017

https://api.elsevier.com/content/article/PII:S0950357905800676?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80067-6

https://api.elsevier.com/content/article/PII:S0950357905800676?httpAccept=text/plain

30 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80067-6

Bailliere's clinical rheumatology

30 November 2022

published in

1 reference

17 August 2017

volume

5

1 reference

17 August 2017

issue

3

1 reference

17 August 2017

page(s)

485-491

1 reference

Osteoporosis after long-term corticosteroid treatment of giant cell arteritis

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Polymyalgia rheumatica. Duration of therapy and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Myalgic syndrome with constitutional effects; polymyalgia rheumatica

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Polymyalgia rheumatica and corticosteroids: how much for how long?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

An alternate-day corticosteroid regimen in maintenance therapy of giant cell arteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Decrease of the OKT8 positive T cell subset in polymyalgia rheumatica. Lack of correlation with disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Treatment of polymyalgia rheumatica: lower initial dose

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Polymyalgia rheumatica: a 10-year epidemiologic and clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

A prospective study of 102 patients with the polymyalgia rheumatica syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

C-Reactive Protein in Giant Cell (Cranial, Temporal) Artentis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Polymyalgia rheumatica. Abrupt and gradual withdrawal of prednisolone treatment, clinical and laboratory observations

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

1 reference

7 January 2021

Prognosis in giant-cell arteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Giant cell (cranial) arteritis: a clinical review

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Prognosis and management of polymyalgia rheumatica

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Reversal of blindness in temporal arteritis with methylprednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Polymyalgia rheumatica and giant cell arteritis: a seven-year survey

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Treatment of polymyalgia rheumatica

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Clinical usefulness of temporal artery biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

Temporal arteritis and its treatment with cortisone and A.C.T.H.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980067-6

1 reference

7 January 2021

Temporal arteritis in Israel. A review of 47 patients

series ordinal

19

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80067-6

Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. A ten-year survey of 53 patients

30 November 2022

series ordinal

41

1 reference

https://api.crossref.org/works/10.1016/S0950-3579(05)80067-6

30 November 2022

Identifiers

1 reference

17 August 2017

1 reference